

Express Mail No.: EV869874291US
Date of Deposit: January 3, 2008



Page 1 of 2
Attorney Docket No.: 23239-544

Please type a plus sign (+) in this box

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/729,581	
				Filing Date		December 3, 2003	
				First Named Inventor		Keefe	
				Group Art Unit		1637	
				Examiner Name		Mark Staples	
				Attorney Docket Number		23239-544	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B20	WO	95/07364	NEXAGEN, INC.	03/16/95		
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C109	Bridonneau et al., "Purification of highly modified RNA-aptamer Effect of complete denaturation during chromatography on product recovery and specific activity", <i>J. Chromatography B</i> 726(1-2):237-247 (1999)					
	C110	Burmeister et al., "Direct In Vitro Selection of a 2'-O-Methyl Aptamer to VEGF", <i>Chem. Biol.</i> 12(1):25-33 (2005)					
	C111	Burmeister et al., "2'-Deoxy Purine, 2'-O-Methyl Pyrimidine (dRmY) Aptamers as Candidate Therapeutics", <i>Oligonucleotides</i> 16(4):337-351 (2006)					
	C112	Chelliserrykattil et al., "Evolution of a T7 RNA polymerase variant that transcribes 2'-O-methyl RNA", <i>Nat. Biotechnol.</i> 22(9):1155-1160 (2004)					
	C113	Fa et al., "Expanding the Substrate Repertoire of a DNA Polymerase by Directed Evolution", <i>J. Am. Chem. Soc.</i> 126(6):1748-1754 (2004)					
	C114	Gudima et al., "Synthesis of mixed ribo/deoxyribopolynucleotides by mutant T7 RNA polymerase", <i>FEBS Lett.</i> 439(3):302-306 (1998)					

	C115	Kostyuk et al., "Mutants of T7 RNA polymerase that are able to synthesize both RNA and DNA", <i>FEBS Lett.</i> 369(2-3):165-168 (1995)
	C116	Majlessi et al., "Advantages of 2'-O-methyl oligoribonucleotide probes for detecting RNA targets", <i>Nuc. Acids Res.</i> 26(9):2224-2229 (1998)
	C117	Ruckman et al., "2'-Fluoropyrimidine RNA-Based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF ₁₆₅)", <i>J. Biol. Chem.</i> 273(32):20556-20567 (1998)
	C118	Uhlmann et al., "15 Use of Minimally Modified Antisense Oligonucleotides for Specific Inhibition of Gene Expression", <i>Meth. Enzymol.</i> 313:268-284 (2000)
	C119	Supplementary European Search Report for EP 03 81 2519

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.